Cancer, Rethought

Premium

Studying cancer is an enormous undertaking. Many researchers spend their lives trying to understand the genetic origins of the disease in its many forms, and how to stop it in its tracks. While most concentrate their efforts on a specific type of cancer, there are others who have taken on an even more difficult task: studying all cancers at the same time to try to determine which mutations in the cancer genome actually affect human health, and which ones don't. It's a task too large for any one lab, says the Dana-Farber Cancer Institute's Rameen Beroukhim.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.